Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma [0.03%]
流行病学和临床数据将脑垂体催乳素分泌腺瘤与醋酸甲羟孕酮注射制剂联系起来
Brooke C Braman,Martha A Cady,Allison A Merz-Herrala et al.
Brooke C Braman et al.
Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based...
TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas [0.03%]
特罗凯-01：一项关于 trametinib 治疗I型神经纤维瘤病儿童患者丛状神经纤维瘤的2期研究
Dorsa Sadat Kiaei,Maxime Caru,Valérie Larouche et al.
Dorsa Sadat Kiaei et al.
Background: Plexiform neurofibromas (PNs) are observed in up to 50% of patients with neurofibromatosis type 1 (NF1). Trametinib has been used widely to treat PNs but limited data has been reported on its efficacy within a...
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma [0.03%]
冷静的乐观态度：精准医疗时代儿科低级别胶质瘤的进展
Chelsea Kotch,Sebastien Perreault,Phoebe Power et al.
Chelsea Kotch et al.
The clinical trial landscape of molecularly targeted treatments for pediatric low-grade glioma (pLGG) has created an exciting and hopeful era for both patients and clinicians alike. Despite numerous clinical trials investigating the use of ...
cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas [0.03%]
CIMPACT-NOW更新12：基于病理学的IDH突变型胶质瘤风险分层和分级的优化研究
Daniel J Brat,Kenneth Aldape,Pim J French et al.
Daniel J Brat et al.
A working group of cIMPACT-NOW evaluated the literature on IDH-mutant gliomas for opportunities to improve pathology-based risk stratification and grading, especially at the interface of CNS WHO grade 2 and 3, since therapeutic decisions de...
Chanawee Hirunpattarasilp,Herbert B Newton
Chanawee Hirunpattarasilp
Brain metastases are a prevalent disease found in up to 40% of patients with solid cancers, and are associated with significant morbidity and mortality. Current treatment options for brain metastases are limited, especially because the tumo...
Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant Meningiomas [0.03%]
现代分子分型重新诠释NRG/RTOG 0539试验，并揭示了隐藏的高危和放疗抵抗性脑膜瘤
Leeor S Yefet,Alexander P Landry,C Leland Rogers et al.
Leeor S Yefet et al.
Background: Meningiomas exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but tumor-control is variable, and biomarkers are limited. NRG/RTOG-0539 is the first prospective phase 2 trial ...
Metabolic and Molecular Correlates of Medulloblastoma: Identification of Molecular Groups Using In Vivo 1H-MR Spectroscopy [0.03%]
髓母细胞瘤的代谢和分子关联：使用体内氢磁共振波谱法识别分子亚型
Benita Tamrazi,Alexander Markowitz,Ashley S Margol et al.
Benita Tamrazi et al.
Background: Accurate molecular classification of medulloblastoma is critical for prognosis and treatment planning, but current methods rely on surgical tissue sampling and molecular profiling. This study evaluated whether...
Corrigendum to: Multiomic profiling of glioblastoma metabolic lesions reveals complex intratumoral genomic evolution and dipeptidase-1-driven vascular proliferation [0.03%]
glioblastoma代谢病灶的多组学分析揭示了复杂的肿瘤内基因组演化和二肽酶-1驱动的血管增殖的勘误版
Published Erratum
Neuro-oncology. 2026 May 11:noag091. DOI:10.1093/neuonc/noag091 2026
Gods do play dice: The activity of regorafenib in glioblastoma not confirmed [0.03%]
上帝在掷骰子吗？regorafenib治疗胶质母细胞瘤的效果未被证实
Martin J van den Bent
Martin J van den Bent